Navigation Links
FDA Agrees With AtheroNova's Clinical Development Plan as Proposed
Date:12/14/2011

IRVINE, Calif., Dec. 14, 2011 /PRNewswire/ -- AtheroNova Inc. (OTCBB: AHRO) ("AtheroNova"), a biotech company focused on the research and development of compounds to regress atherosclerotic plaque has established a clear development plan, including Phase I and Phase II protocol outlines, based on the recently finalized minutes of its pre-IND (Investigational New Drug) meeting with the U.S. Food and Drug Administration (FDA) for its AHRO-001, a compound for the treatment of atherosclerosis.  The Company has incorporated guidance from the FDA and is moving forward with its IND enabling activities.  In addition, the sourcing and production of the Active Pharmaceutical Ingredient (API) is progressing according to schedule. 

"As a result of the supportive feedback from the FDA, we have established a clear development plan for AHRO-001, including Phase I and Phase II human clinical studies." said Thomas W. Gardner, CEO of AtheroNova.  "Based on the success of our interactions with the FDA, AtheroNova plans to move forward with the submission of the IND application during 2012, as planned." 

"The imaging of plaque lesions has made significant strides in the last few years and AtheroNova is planning to use the state of the art combination of intravascular/near-infrared spectroscopy as a critical measurement tool for the regression of coronary artery disease when moving forward with its Phase I and Phase II studies," said Balbir Brar, DVM, PhD; SVP, Drug Development of AtheroNova.  "Critical information of the coronary plaque morphology and lipid content will assist in the measurement of clinical progress of this and future therapies in plaque management.  We appreciate FDA's suggestions in AtheroNova's study outlines and acceptance of intravascular/near-infrared spectroscopy use in evaluating plaque reversibility."

About AHRO-001

AHRO-001 is AtheroNova's first novel application for the treatment and p
'/>"/>

SOURCE AtheroNova Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Zimmer Holdings, Inc. Agrees to Sell $550 Million of Senior Notes
2. 1-800-GET-THIN Agrees With Report Calling for Better Eating Habits
3. ARAMARK Agrees to Sell its Galls Business to CI Capital Partners
4. Valeant Pharmaceuticals Agrees to Acquire Ortho Dermatologics
5. Valeant Pharmaceuticals Agrees to Acquire Dermik
6. BioMarin Agrees to Acquire Biologics Manufacturing Plant in Ireland from Pfizer
7. Devicorâ„¢ Medical Products, Inc. Agrees to Acquire Neoprobes Gamma Detection Devices
8. Biofield Corporations 51% Owned Subsidiary Agrees to Deal Appointing McKinley Infocapital as Korean Exclusive Distributor of Breast Cancer Diagnostic System; Contract has Potential Value of up to $15.3 Million
9. Quest Diagnostics Agrees to Repurchase 15.4 Million Shares From Largest Shareholder
10. Xanodyne Agrees to Withdraw Propoxyphene From the U.S. Market
11. Boston Scientific Agrees to Sell Neurovascular Business to Stryker
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/22/2014)... , Aug. 22, 2014  Cannabis Science, Inc. ... formulation-based drug development and related consulting, is pleased ... international medical cannabis conference taking place at the ... , on October 22, 2014.  The multilingual ... such as researchers, health professionals, and patients, to ...
(Date:8/22/2014)...  WaferGen Bio-systems, Inc. (NASDAQ: WGBS) today announced the ... common stock and warrants at a price of $10,000 ... to deducting underwriting discounts and commissions and offering expenses ... immediately separable and will be issued separately.  The shares ... The NASDAQ Stock Market under the ticker symbol "WGBS" ...
(Date:8/21/2014)... Aug. 21, 2014  Vermillion, Inc. (NASDAQ: ... cancers and women,s health, has appointed Holly B. ... Markets. Ms. Bauzon has a proven track ... coverage for laboratory services companies. She has more than ... Inc., where she held the position of Director, Lab ...
Breaking Medicine Technology:Cannabis Science, Inc. (CBIS) to Sponsor 3rd International Conference on Cannabinoids in Medicine in October 2014 in Strasbourg, France 2Cannabis Science, Inc. (CBIS) to Sponsor 3rd International Conference on Cannabinoids in Medicine in October 2014 in Strasbourg, France 3WaferGen Bio-Systems Announces Pricing of $20 Million Underwritten Offering and Uplisting to NASDAQ 2WaferGen Bio-Systems Announces Pricing of $20 Million Underwritten Offering and Uplisting to NASDAQ 3WaferGen Bio-Systems Announces Pricing of $20 Million Underwritten Offering and Uplisting to NASDAQ 4Vermillion Appoints Holly B. Bauzon as VP of Sales and Managed Markets 2
... from a Phase 1/2 study of perifosine in combination ... from or refractory to bortezomib , ... Biopharmaceuticals, Inc. (Nasdaq: KERX ) today announced ... combination with bortezomib (+/- dexamethasone) in patients with relapsed/refractory ...
... SOUTH SAN FRANCISCO, Calif., Dec. 9 Portola,Pharmaceuticals, ... advances in cardiovascular disease, inflammatory disease,and cancer, today ... a large Phase II clinical trial of PRT060128, ... undergoing non-urgent,percutaneous coronary intervention (PCI). , ...
Cached Medicine Technology:Keryx Biopharmaceuticals, Inc. Reports Phase 1/2 Data on KRX-0401 (Perifosine) at 50th Annual Meeting of American Society of Hematology 2Keryx Biopharmaceuticals, Inc. Reports Phase 1/2 Data on KRX-0401 (Perifosine) at 50th Annual Meeting of American Society of Hematology 3Keryx Biopharmaceuticals, Inc. Reports Phase 1/2 Data on KRX-0401 (Perifosine) at 50th Annual Meeting of American Society of Hematology 4Keryx Biopharmaceuticals, Inc. Reports Phase 1/2 Data on KRX-0401 (Perifosine) at 50th Annual Meeting of American Society of Hematology 5Keryx Biopharmaceuticals, Inc. Reports Phase 1/2 Data on KRX-0401 (Perifosine) at 50th Annual Meeting of American Society of Hematology 6Keryx Biopharmaceuticals, Inc. Reports Phase 1/2 Data on KRX-0401 (Perifosine) at 50th Annual Meeting of American Society of Hematology 7Portola Pharmaceuticals Initiates Phase II Trial of Novel IV and Oral Anti-Platelet Drug in Non-Urgent Percutaneous Coronary Intervention 2Portola Pharmaceuticals Initiates Phase II Trial of Novel IV and Oral Anti-Platelet Drug in Non-Urgent Percutaneous Coronary Intervention 3
(Date:8/22/2014)... stenting to open blockages in the kidney arteries ... from modern clinical trials, according to new recommendations ... and Cardiovascular Interventions today by the Society ... Hospitals Case Medical Center,s Sahil Parikh, MD, Director, ... Case Western Reserve University School of Medicine was ...
(Date:8/22/2014)... 2014 (HealthDay News) -- Counseling may do little to ... finds. Researchers analyzed 66 studies that included nearly ... at high risk for drinking problems. Participants in 49 ... in the rest of the studies attended group sessions ... A counseling technique called motivational interviewing was used in ...
(Date:8/22/2014)... A new, online conference is coming August 25th-29th, 2014 about ... open to everyone. Over 20 top experts will be ... how to stop emotional eating, start eating healthier and successful ... not a diet. The concept is about how to make ... don't eat that" approach. , You can sign up for ...
(Date:8/22/2014)... 22, 2014 Key West Health & ... revealed their much anticipated study results of the 12 ... and released an accompanying infographic on their website. It ... have a major impact on the skin and contribute ... more. , When asked how they determined the results, ...
(Date:8/22/2014)... Medical Oncology (ESMO), the leading pan-European organisation representing ... three outstanding individuals receiving the Society,s esteemed annual ... Bokemeyer, Heikki Joensuu and Peter Boyle on the ... Madrid, Spain. , Carsten Bokemeyer will receive the ... transition of cancer discovery into real benefit at ...
Breaking Medicine News(10 mins):Health News:UH Case Medical Center's Dr. Parikh authors SCAI paper on renal artery stenosis treatment 2Health News:UH Case Medical Center's Dr. Parikh authors SCAI paper on renal artery stenosis treatment 3Health News:Counseling Does Little to Deter Youth Drinking, Review Finds 2Health News:20 Top Experts Discuss How to Unravel the Food-Mood Connection 2Health News:Key West Health & Beauty Announces The 12 Best & Worst U.S. Cities For Skin Study 2Health News:ESMO honors outstanding oncology professionals 2Health News:ESMO honors outstanding oncology professionals 3
... , FRIDAY, April 27 (HealthDay News) -- Two genetic ... as primary open-angle glaucoma, according to new research. Glaucoma ... U.S. National Eye Institute said in a news release. ... worldwide, is due to irreversible damage to the optic nerve," ...
... the structure of a key part of the human obesity ... which could help provide new treatments for the complications of ... in the journal Structure , will greatly enhance the ... the receptor for the obesity hormone leptin. This could have ...
... , FRIDAY, April 27 (HealthDay News) -- Children who are bullied ... time they are 12 years old, according to a new study. ... the United Kingdom said its findings, published online April 27 in ... for this type of behavior. Examples of self-harming behaviors ...
... 5th Annual Jean Sindab Triple Negative Breast Cancer ... Emory University, provides an intimate learning environment in ... cancers (TNBC) will be explored. Nationally recognized speakers ... on current research in TNBC. TNBC affects young ...
... the discovery of small molecules that kill cancer cells ... results, in both cell and mouse models, demonstrate that ... by viral proteins, thus killing the infected tumor cells. ... April 20 issue of the journal Chemistry & ...
... ATLANTA April 26, 2012 New guidelines from ... a healthy weight, getting adequate physical activity, and eating ... and increase the likelihood of disease-free survival after a ... and Physical Activity Guidelines for Cancer Survivors, published early ...
Cached Medicine News:Health News:Research Gets Closer to Genetic Roots of Glaucoma 2Health News:New drug to tackle fat problems 2Health News:Bullied Children at Greater Risk for Self-Harm, Study Finds 2Health News:Small molecular bodyguards kill HPV-infected cancer cells by protecting tumor-suppressor 2Health News:Small molecular bodyguards kill HPV-infected cancer cells by protecting tumor-suppressor 3Health News:Guidelines say diet, exercise, weight control improve odds after cancer diagnosis 2Health News:Guidelines say diet, exercise, weight control improve odds after cancer diagnosis 3
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: